Top Markets
Coin of the day
Poolbeg Pharma PLC Poolbeg Pharma PLC

Poolbeg Pharma PLC

POLB
株式のランク #38625
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the... Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
株価
$0.11565963
時価総額
$882.99K
変化(1日)
-2.30%
変化(1年)
189.81%
GB
取引 Poolbeg Pharma PLC (POLB)

カテゴリー

Poolbeg Pharma PLC(POLB)の利益
2026 時点の利益 TTM: 0
Poolbeg Pharma PLC の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Poolbeg Pharma PLC の利益の推移(2026 〜 2026)
各年末の利益
利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益